Brian Taylor
Psychiatry · Ventura, CANPI 1992905723
Payments from drug & device makers
Across 105 payments — averaging $28.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$795
- Johnson & Johnson$526
- Alkermes, Inc.$362
- Otsuka America Pharmaceutical, Inc.$239
- AbbVie$214
- Lundbeck LLC$173
- plus $677 from 11 others
What the payments were for
- Food & beverage$2,90897%
- Education$773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $795 |
| Johnson & Johnson | 11 | $526 |
| Alkermes, Inc. | 9 | $362 |
| Otsuka America Pharmaceutical, Inc. | 3 | $239 |
| AbbVie(2 entities) | 6 | $214 |
| Lundbeck LLC | 9 | $173 |
| E.r. Squibb & Sons, L.L.C. | 2 | $129 |
| Tris Pharma Inc | 1 | $125 |
| Biogen | 1 | $118 |
| Neurocrine Biosciences, Inc. | 2 | $104 |
| Bausch Health US, LLC | 3 | $70 |
| Sage Therapeutics, LLC | 2 | $33 |
| Tempus AI, Inc | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Neos Therapeutics, LP | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- SPRAVATO$267
- ARISTADA INITIO$125
- Quillivant$125
- Quillichew ER$125
- Dyanavel XR$125
- REXULTI$125
- Zurzuvae$118
- COBENFY$108
How this compares
$2,985 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 24 | $3,352 |
| Oxcarbazepine | 17 | $1,176 |
| Olanzapine | 12 | $280 |
| Quetiapine Fumarate | 26 | $256 |
| Escitalopram Oxalate | 25 | $235 |
| Buspirone Hcl | 31 | $222 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $145 |
| Trazodone Hcl | 42 | $132 |
| Sertraline Hcl | 19 | $113 |
| Lamotrigine | 12 | $76 |
| Lorazepam | 14 | $30 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Ventura
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.